Survey Open! Community Perceptions and Preferences Regarding Long-Acting Technologies for TB Treatment and Prevention

6 June 2025

Long-acting injectables (LAIs) for the treatment and prevention of TB are currently under development. Community engagement and input is critical in the early stages of this work to ensure that new technologies are designed to best suit the needs and preferences of TB affected communities.

Treatment Action Group (TAG) is working with the World Health Organization (WHO) to gather community perspectives on the preferred characteristics of long-acting injectables for TB to help inform the design and development of these technologies so that they meet the needs of people affected by TB.

As part of that work, a short survey in launched on Community Perceptions and Preferences Regarding Long-Acting Technologies for TB Treatment and Prevention. Responses will inform the development of the WHO’s Target Regimen Profile for long-acting injectables for TB treatment and prevention and help drug developers design technologies that meet the needs of people affected by TB, healthcare providers, and health systems.

The survey is offered in the following languages: English, Español, Français, Русский and should take 15-20 minutes to complete. The survey in open until 23 June 2025.  Your support in completing the survey will be deeply appreciated!

Before taking the survey, you may want to refer to a recent webinar designed to provide important background and other information about long-acting technologies that may be helpful in responding to the survey questions. The recording and slides are available here.